Skip to main
IMVT
IMVT logo

Immunovant Inc (IMVT) Stock Forecast & Price Target

Immunovant Inc (IMVT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Immunovant Inc. has demonstrated a strong potential for its candidate IMVT-1402, evidenced by a sustained reduction in TRAb levels throughout the off-treatment period, which indicates the disease-modifying capabilities of FcRn blockers in Graves' disease. The company reported a remarkable responder rate of 81% in patients during the six-month off-treatment phase, paralleling the 70%-80% responder rates observed during active treatment. This data not only highlights the efficacy of its treatment but also instills confidence in the durability of effects in a population previously unresponsive to existing therapies, reinforcing the positive outlook for the company's future.

Bears say

Immunovant Inc is currently engaged in the development of IMVT-1402 to address autoimmune diseases, yet its financial outlook appears challenged due to several persistent issues. High levels of thyroid stimulating hormone receptor antibodies (TRAbs) are correlated with increased relapse rates and complications, which may hinder the clinical success of its drug candidate and affect market adoption. Additionally, the potential for serious complications, such as inflammation that can compress the optic nerve, raises concerns regarding the overall viability and safety profile of Immunovant's treatment approaches, potentially impacting investor confidence and future revenues.

Immunovant Inc (IMVT) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunovant Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunovant Inc (IMVT) Forecast

Analysts have given Immunovant Inc (IMVT) a Buy based on their latest research and market trends.

According to 7 analysts, Immunovant Inc (IMVT) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunovant Inc (IMVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.